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Abstract
Introduction: In Malawi, HIV-infected pregnant and breastfeeding women are offered lifelong antiretroviral therapy (ART)
regardless of CD4 count or clinical stage (Option B+). Their HIV-exposed children are enrolled in the national prevention of
mother-to-child transmission (PMTCT) programme, but many are lost to follow-up. We estimated the cumulative incidence of
vertical HIV transmission, taking loss to follow-up into account.
Methods: We abstracted data from HIV-exposed children enrolled into care between September 2011 and June 2014 from
patient records at 21 health facilities in central and southern Malawi. We used competing risk models to estimate the
probability of loss to follow-up, death, ART initiation and discharge, and used pooled logistic regression and inverse
probability of censoring weighting to estimate the vertical HIV transmission risk.
Results: A total of 11,285 children were included; 9285 (82%) were born to women who initiated ART during pregnancy. At
age 30 months, an estimated 57.9% (95% CI 56.6–59.2) of children were lost to follow-up, 0.8% (0.6–1.0) had died, 2.6%
(2.3–3.0) initiated ART, 36.5% (35.2–37.9) were discharged HIV-negative and 2.2% (1.5–2.8) continued follow-up. We
estimated that 5.3% (95% CI 4.7–5.9) of the children who enrolled were HIV-infected by the age of 30 months, but only
about half of these children (2.6%; 95% CI 2.3–2.9) were diagnosed.
Conclusions: Confirmed mother-to-child transmission rates were low, but due to poor retention only about half of HIV-
infected children were diagnosed. Tracing of children lost to follow-up and HIV testing in outpatient clinics should be scaled
up to ensure that all HIV-positive children have access to early ART.
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Introduction
In sub-Saharan Africa, every year 1.4 million children are born
to HIV-positive women [1]. Without intervention, 30–45% of
the women transmit HIV to their children [2]. With effective
antiretroviral therapy (ART) mother-to-child transmission can
be reduced to less than 5% [3]. In the last years, huge progress
has been made in the global efforts to eliminate HIV mother-
to-child transmission [4]. Since 2013, the World Health
Organization (WHO) recommends that all HIV-positive preg-
nant and breastfeeding women are offered lifelong ART
according to its “Option B+” guidelines [5]. Most countries
with high burden of HIV have implemented Option B+. As a
consequence, the ART coverage in pregnant women increased
and the number of new HIV infections in children
declined [1,6].
Despite progress with prevention of HIV mother-to-child
transmission, a substantial number of children are still get-
ting infected [1]. Many of them are born to women who
were not diagnosed with HIV, did not initiate ART, discon-
tinued ART or adhered poorly to treatment [7–9]. Infants
and young children living with HIV are at a very high risk of
mortality: every second untreated HIV-infected child dies
before the age of 2 years [10,11]. It is therefore crucial that
HIV-positive children are diagnosed and treated soon after
infection [10–12]. To ensure timely HIV diagnosis and
access to ART, the WHO recommends that children born
to HIV-positive women (HIV-exposed children) are regularly
followed-up and tested for HIV [5,12]. In Malawi, HIV-
exposed children are enrolled in the national prevention
of mother-to-child transmission (PMTCT) programme and
regularly tested for HIV. Children diagnosed with HIV are
referred to the ART clinic and initiate ART [13].
Recent data from the National Evaluation of Malawi’s
PMTCT Programme (NEMAPP) showed that mother-to-
child transmission antepartum and intrapartum was low
with Option B+: 3.9% of the 4–12-week-old children born
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to HIV-infected mothers were found HIV-positive [14].
While Option B+ successfully prevents antepartum and
intrapartum mother-to-child transmission, the policy may
prevent postpartum transmission less effectively, because
many postpartum women adhere poorly to ART, or discon-
tinue therapy before weaning of breastfeeding [8,9].
Children at higher risk of HIV transmission (i.e. those born
to mothers not on ART) are less likely to be retained in care
and tested for HIV and thus are underrepresented in routi-
nely collected national data [15–18]. For these reasons, the
overall effectiveness of Option B+ for PMTCT at the end of
breastfeeding is currently unknown.
We estimated the cumulative incidence of HIV infection
at the end of breastfeeding among HIV-exposed children
enrolled in Malawi’s PMTCT programme, taking into
account unobserved HIV test results from children who
were lost to follow-up or not tested. We also estimated
cumulative retention of HIV-exposed children in the pro-
gramme, loss to follow-up, ART initiation and mortality.
Methods
Malawi’s mother-to-child transmission programme
In Malawi, HIV-positive pregnant and breastfeeding
women are offered lifelong ART according to WHO’s
Option B+ policy. HIV-exposed children are enrolled in
the national PMTCT programme as soon after birth as
possible. Clinic follow-up of children begins at 6 weeks of
age. During the first 6 months, children are seen
monthly, thereafter every 3 months. Children receive
nevirapine prophylaxis for 6 weeks and cotrimoxazole
prophylaxis until their final negative HIV status has
been confirmed. They are HIV tested with a HIV-1 DNA
polymerase chain reaction test at 6 weeks of age, and
again with rapid antibody testing when they are 12 and
24 months old. Children are again tested 6 weeks after
weaning of breastfeeding to confirm the final negative
HIV status before they are discharged. Children diag-
nosed with HIV are referred for ART initiation [13].
Study design and participants
We included HIV-exposed children who enrolled in Malawi’s
national PMTCTprogrammebetween1 September 2011 and30
June 2014 at one of the 21 large health facilities including health
centres, district hospitals, faith-based hospitals and central hos-
pitals from a diverse geographical area in the central and south-
ern region ofMalawiwho participated in our previous studies of
the implementation of Option B+ in Malawi [7–9]. We selected
these facilities because they were using the Baobab Health
Antiretroviral Therapy (BART) electronic medical record system
in September 2011, when the Option B+ programme was
launched. Health facilities were classified by the Ministry of
Health. Health centres are primary-care facilities, district and
faith-based hospitals are secondary-care facilities and central
hospitals are tertiary-care facilities. Faith-based hospitals are
operated by faith-based organizations. We followed the chil-
dren up to 26 June 2015.We excluded childrenwhose birthdate
was missing, and children born to mothers who received ante-
partum antiretroviral (ARVs) medication that were no longer
recommended in the Malawi’s Integrated HIV Management
guidelines (Figure 1) [13].
Procedures
Registration and follow-up data for HIV-exposed children
enrolled in the HIV care programme are routinely collected
on standardized paper-based forms kept at the health facil-
ities. Paper-based records were manually captured into an
electronic database. To reduce data entry errors, data entry
clerks entered the records twice, independently.
Inconsistencies were resolved by a third reviewer.
Registers were de-duplicated using probabilistic record link-
age methods. More details on data collection are given in
the appendix (Text S1).
Outcomes
We analysed the risk of mother-to-child transmission and
PMTCT programme outcomes. The endpoints for mother-
to-child transmission were the unweighted (observed)
cumulative incidence of HIV infection, and the weighted
cumulative incidence of HIV infection defined as the sum
Figure 1. Flow chart of eligibility of study participants.
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of the observed cumulative incidence of HIV infection plus
the unobserved cumulative incidence of HIV infection in
children who were lost to follow-up or not tested for HIV
(i.e., the risk of HIV infection that we would have observed
if all enrolled children were retained and tested according
to the guidelines, after 6 weeks, 12 months and 24 months)
[13]. Children were classified as HIV-infected if they tested
positive with HIV-1 DNA testing at any time during follow-
up, or if their HIV rapid antibody test was positive when
they were 12 months or older, or if they were presump-
tively diagnosed, based on clinical conditions that consti-
tute presumed severe HIV disease and a positive HIV rapid
test before they were 12 months old and no later negative
test [13]. The endpoints for PMTCT programme outcomes
were the estimated proportions of children not yet enrolled
into care, retained in care, lost to follow-up, discharged
confirmed HIV-free, initiated ART and the proportion of
children who died. Children who missed a clinic appoint-
ment for more than 60 days and did not return to care
thereafter were classified as lost to follow-up. Children who
had received a negative HIV test result at least 6 weeks
after the end of breastfeeding were discharged confirmed
HIV-free. Children were classified as retained in care if they
had enrolled into care, and had not been discharged con-
firmed HIV-free, were not lost to follow-up, had not trans-
ferred out, had not initiated ART and had not died.
Statistical analyses
Risk of mother-to-child transmission
We estimated unweighted and weighted Kaplan–Meier fail-
ure functions for children’s cumulative incidence of HIV
infection in pooled logistic regression. We used inverse
probability of censoring weighting to account for HIV infec-
tions that would have been observed if all children who
enrolled were retained in care and tested according to the
guidelines [19,20]. In the weighted analysis, children who
were not tested were represented by children who had
similar characteristics and were tested. Characteristics
considered included infant nevirapine prophylaxis at birth
(no, yes, unknown), infant nevirapine prophylaxis after
birth (no, yes, unknown), ARVs given to mother during
pregnancy (none, mother on triple ART for <4 weeks,
mother on triple ART ≥4 weeks, unknown), ARVs given to
mother in labour (none, single dose nevirapine, mother on
triple ART, unknown), type of facility (faith-based hospital,
health centre, district hospital, central hospital), time-
updated maternal ART coverage during breastfeeding (on
ART, not on ART) and maternal death (yes, no). We calcu-
lated approximate 95% confidence intervals (CIs) for the
cumulative incidence of HIV infection, using an error factor
[21]. We multiplied cumulative incidences by 100 to
express cumulative risk of HIV infection as the percentage
of HIV-infected children. Text S2 provides more details on
the statistical methods we used to estimate the risk of
mother-to-child transmission. The analysis was done in
STATA (version 14) and data were plotted in R (ver-
sion 3.2.2).
PMTCT programme outcomes
We developed a multi-state model within a competing risk
framework to estimate the proportions of children who
experienced six PMTCT programme outcomes: enrolment
into care, retention in care, loss to follow-up, ART initiation,
discharge and death). We fitted the model in the R package
mstate [22,23]. The structure of the model is shown in
Figure 2. From birth to enrolment into care, children were
in State 1 (“not yet enrolled”). On the day they enrolled
into the PMTCT programme, children switched to State 2
(“retained in care”), where they remained until they were
either discharged confirmed HIV-free (State 3), lost to fol-
low-up (State 4), initiated ART (State 5) or died (State 6).
We followed children until the day of discharge, loss to
follow-up, death or ART initiation for a maximum follow-up
time of 30 months. Children were censored if their follow-
up ended, or if they were transferred out. The appendix
contains a technical description of the model (Text S2). We
Figure 2. Multi-state model.
The boxes represent the six states of the multi-state model and the black triangles represent the events that trigger transitions between
states. All children start in State 1 “not yet enrolled” when they are born, and switch to State 2 “retained in care” after they enrolled into HIV
care. Children remain in State 2 until they were discharged HIV-negative (State 3), lost to follow-up (State 4), initiated ART (State 5) or died
(State 6), or else, until their follow-up ended. States 3 to 6 are absorbing states (i.e. children who have entered an absorbing state remain in
this state).
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compared PMTCT programme outcomes between children
at low risk (children who received nevirapine prophylaxis at
and after birth and were born to mothers who received at
least 4 weeks of triple ART) and high risk (children who
received no nevirapine prophylaxis and were born to
mothers who received no triple ART) of mother-to-child
transmission. We predicted and plotted the percentage of
children who had experienced a PMTCT programme out-
come separately for children with the low- and high-risk
profile. The adjusted hazard ratios (aHRs) from the model
we used for the predictions are shown in Table S1.
We fitted a multivariable Cox proportional hazards mod-
els in the framework of the multistate model to estimate
unadjusted and aHRs for predictors of PMTCT programme
outcomes. We considered the following predictors in multi-
variable analysis: gender (male, female, unknown); age at
enrolment (in months); birthweight (≥2500g, <2500g,
unknown); nevirapine prophylaxis at birth; nevirapine pro-
phylaxis after birth; antepartum ARV exposure; intrapartum
ARV exposure; and, facility type.
Ethical considerations
The National Health Sciences Research Committee, Malawi
and the Cantonal Ethics Committee of Bern, Switzerland
granted ethical approval for the study and waived the
requirement to obtain informed consent.
Results
Characteristics of study participants
We included 11,285 HIV-exposed children from 21 health
facilities (Figure 1). Median age at enrolment was
1.7 months (interquartile range (IQR) 1.5–3). Most children
(82.3%) were born to women who received ART during
pregnancy; 9.6% were born to women who received no
antepartum ART. Data on ART exposure during pregnancy
were missing for 8.2% of children. Most infants received
nevirapine prophylaxis at birth (84.0%) and then continued
nevirapine prophylaxis (68.4%) (Table 1).
Risk of mother-to-child transmission
Overall, 288 out of 11,285 children (2.6%) were diagnosed
with HIV. Most children (272, 94.4%) were diagnosed based
on a positive HIV-1 DNA or a positive HIV rapid antibody
test taken after the age of 12 months. Few children (16 of
288, 5.6%) were diagnosed as presumed severe HIV dis-
ease. Figure 3 shows the estimated cumulative incidence of
HIV infection from unweighted and weighted analyses. By
age 8 weeks, 0.7% (95% CI: 0.6–0.9) of the children who
enrolled were diagnosed as HIV infected. The proportion of
children who were diagnosed increased to 2.2% (95% CI:
1.9–2.5) by age 12 months and to 2.6% (95% CI: 2.3–2.9) by
age 30 months. In the weighted analysis, which takes
unobserved test results from children lost to follow-up or
not tested into account, the cumulative incidence was 0.8%
(95% CI: 0.7–1.0) by age 8 weeks, 2.7% (95% CI: 2.4–3.1) by
age 12 months and 5.3% (95% CI: 4.7–5.9) by age
30 months.
PMTCT programme outcomes
Figure 4 shows the proportions of HIV-exposed children
who were not yet enrolled into care, retained in care, lost
to follow-up, discharged HIV-negative, initiated ART or
who died within the first 30 months of their lives. By
the age of 6 months, 12.2% of the children (95% CI: 11.6–
12.8) were not yet enrolled into care. Only few children
(3.8%; 95% CI: 3.5–4.2) enrolled after age 12 months. By
the age of 6 months, 21.5% (95% CI: 20.7–22.3) of the
children were lost to follow-up; this number increased to
31.5% (95% CI: 30.6–32.4) by 12 months, and 57.9% (95%
CI: 56.6–59.2) by 30 months. Documented mortality was
low: 0.8% (95% CI: 0.6–1.0) of the children were known
to have died by the age of 30 months. Most children who
were discharged HIV-free received their final negative HIV
test result between 24 and 30 months. By age 30 months,
36.5% (95% CI: 35.2–37.9) of the children were dis-
charged HIV-negative, 2.6% (95% CI: 2.3–3.0) initiated
ART and 2.2% (95% CI: 1.5–2.8%) were followed beyond
age 30 months.
Table 2 shows the results from the multivariable ana-
lysis of predictors of PMTCT programme outcomes.
Results from univariable analyses are shown in the
appendix in Table S2. Children who enrolled late, those
who received care at health centres and those born to
mothers who did not receive ART during pregnancy were
at the highest risk of loss to follow-up. The aHRs for loss
to follow-up was 1.13 (95% CI: 1.12–1.14) per month
increase in the age at enrolment of the child. Children
born to women who received ART during pregnancy were
much less likely to be lost to follow-up than children of
women who received no ART during pregnancy: for
women who received ART <4 weeks, the aHR of loss to
follow-up was 0.77 (95% CI: 0.65–0.91), and for women
who received ART for ≥4 weeks, the aHR was 0.62 (95%
CI: 0.54–0.72). The risk of loss to follow-up was highest in
central hospitals, followed by health centres, and faith-
based hospitals, and lowest in district hospitals. Children
who received nevirapine prophylaxis, and those born to
women who received ART during pregnancy, enrolled at
younger ages than those who were not exposed to ARV
medication. Low birthweight (<2.500g) and no antepar-
tum ART exposure was associated with ART initiation.
Later enrolment into care and low birthweight was asso-
ciated with increased mortality.
Figure 5 shows the proportions of children not yet
enrolled, retained in care, discharged confirmed HIV-free,
lost to follow-up, initiated ART or dead, for children at low
and high risk of HIV mother-to-child transmission. Children
at high risk of mother-to-child transmission enrolled later
into care, were more likely to be lost to follow-up, more
likely to die, much more likely to initiate ART and less likely
to be discharged HIV-negative than children at low risk of
mother-to-child transmission.
Discussion
We estimated that just over 5% of the HIV-exposed children
enrolled in Malawi’s PMTCT programme were HIV-infected
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Table 1. Characteristics of children enrolled into HIV care by HIV care outcomes
HIV care outcomes
Retained in care
(N = 4625)
Transferred out
(N = 192)
Discharged HIV-
(N = 1514)
Lost to follow-up
(N = 4662)
Died
(N = 72)
Initiated ART
(N = 220)
Gender (%)
Male 2168 (41.1%) 98 (1.9%) 712 (13.5%) 2169 (41.1%) 32 (0.6%) 97 (1.8%)
Female 2196 (40.4%) 85 (1.6%) 743 (13.7%) 2260 (41.6%) 36 (0.7%) 115 (2.1%)
Unknown 261 (45.5%) 9 (1.6%) 59 (10.3%) 233 (40.6%) 4 (0.7%) 8 (1.4%)
Age at enrolment (%)
<6 weeks 770 (36.2%) 44 (2.1%) 246 (11.6%) 1015 (47.7%) 21 (1.0%) 33 (1.6%)
6–12 weeks 3008 (48.7%) 97 (1.6%) 729 (11.8%) 2236 (36.2%) 30 (0.5%) 75 (1.2%)
3–6 months 523 (32.7%) 30 (1.9%) 257 (16.1%) 742 (46.4%) 11 (0.7%) 37 (2.3%)
>6 months 324 (23.5%) 21 (1.5%) 282 (20.4%) 669 (48.4%) 10 (0.7%) 75 (5.4%)
Median (IQR) age in
months
1.6 (1.5–2.3) 1.7 (1.4–3.1) 1.9 (1.5–4.4) 1.8 (1.5–3.5) 1.6 (1.4–3.4) 2.9 (1.6–7.2)
Year of birth (%)
2011 38 (2.8%) 25 (1.8%) 404 (29.5%) 857 (62.5%) 11 (0.8%) 36 (2.6%)
2012 880 (20.2%) 72 (1.7%) 890 (20.4%) 2393 (54.9%) 36 (0.8%) 90 (2.1%)
2013 2893 (63.8%) 80 (1.8%) 212 (4.7%) 1243 (27.4%) 24 (0.5%) 84 (1.9%)
2014 814 (80.0%) 15 (1.5%) 8 (0.8%) 169 (16.6%) 1 (0.1%) 10 (1.0%)
Birthweight (%)
<2.5 kg 641 (41.9%) 28 (1.8%) 190 (12.4%) 611 (39.9%) 24 (1.6%) 37 (2.4%)
≥2.5 kg 2631 (41.4%) 118 (1.9%) 794 (12.5%) 2688 (42.3%) 31 (0.5%) 94 (1.5%)
Missing 1353 (39.8%) 46 (1.4%) 530 (15.6%) 1363 (40.1%) 17 (0.5%) 89 (2.6%)
Median (IQR) in kg 3 (2.7–3.4) 3 (2.7–3.4) 3 (2.7–3.4) 3 (2.7–3.4) 2.8 (2.4–3.2) 3 (2.5–3.3)
Antepartum ART
exposure (%)
None 226 (20.9%) 22 (2.0%) 169 (15.6%) 559 (51.8%) 15 (1.4%) 89 (8.2%)
ART <4 weeks 397 (41.4%) 16 (1.7%) 109 (11.4%) 415 (43.3%) 3 (0.3%) 19 (2.0%)
ART ≥4 weeks 3754 (45.1%) 145 (1.7%) 1109 (13.3%) 3171 (38.1%) 48 (0.6%) 99 (1.2%)
Unknown 248 (27.0%) 9 (1.0%) 127 (13.8%) 517 (56.2%) 6 (0.7%) 13 (1.4%)
Intrapartum ARV
exposure (%)
None 290 (23.4%) 27 (2.2%) 221 (17.8%) 595 (48.0%) 16 (1.3%) 91 (7.3%)
sdNVP 113 (33.0%) 4 (1.2%) 63 (18.4%) 152 (44.4%) 5 (1.5%) 5 (1.5%)
ART 3935 (45.1%) 147 (1.7%) 1110 (12.7%) 3380 (38.7%) 47 (0.5%) 114 (1.3%)
Unknown 287 (29.6%) 14 (1.4%) 120 (12.4%) 535 (55.2%) 4 (0.4%) 10 (1.0%)
NVP at birth (%)
None 302 (25.7%) 24 (2.0%) 213 (18.1%) 534 (45.4%) 12 (1.0%) 90 (7.7%)
Yes 4151 (43.8%) 160 (1.7%) 1226 (12.9%) 3773 (39.8%) 56 (0.6%) 119 (1.3%)
Unknown 172 (27.5%) 8 (1.3%) 75 (12.0%) 355 (56.8%) 4 (0.6%) 11 (1.8%)
NVP after birth (%)
None 616 (31.2%) 30 (1.5%) 355 (18.0%) 854 (43.3%) 16 (0.8%) 103 (5.2%)
Yes 3487 (45.2%) 139 (1.8%) 978 (12.7%) 2980 (38.6%) 40 (0.5%) 96 (1.2%)
Unknown 522 (32.8%) 23 (1.4%) 181 (11.4%) 828 (52.0%) 16 (1.0%) 21 (1.3%)
Facility type (%)
Health centre 684 (48.5%) 11 (0.8%) 59 (4.2%) 639 (45.3%) 0 (0.0%) 18 (1.3%)
District hospital 3224 (41.4%) 119 (1.5%) 1220 (15.7%) 3010 (38.7%) 47 (0.6%) 162 (2.1%)
Faith-based hospital 397 (39.2%) 20 (2.0%) 117 (11.5%) 442 (43.6%) 12 (1.2%) 26 (2.6%)
Central hospital 320 (29.7%) 42 (3.9%) 118 (10.9%) 571 (53.0%) 13 (1.2%) 14 (1.3%)
Data are number of children (row %) if not otherwise stated.
ARV: antiretroviral drugs; ART: antiretroviral therapy; NVP: nevirapine prophylaxis.
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by the age of 30 months, but due to high loss to follow-up
only about half of these children were diagnosed in the
programme. About 80% of children received nevirapine
prophylaxis and were born to women who received ART,
but retention of children in the PMTCT programme was
poor: almost two thirds were lost to follow-up and only
one third of the children were discharged confirmed HIV-
negative. Children who enrolled late, those who did not
receive nevirapine prophylaxis and those who were born to
women who did not receive ART during pregnancy were at
highest risk of loss to follow-up.
Our study is the first to estimate the risk of mother-to-
child transmission at the end of breastfeeding in
Malawi’s Option B+ programme. The median duration
of breastfeeding in Malawi is 23 months and only few
children were still breast-fed beyond our follow-up dura-
tion [24]. A strength of our study is that we adjusted our
estimates for HIV transmission to take into account
unobserved HIV test results from children lost to follow-
up or not tested, and that we thus could estimate the
cumulative incidence of HIV infection for all children
enrolled in the PMTCT programme [19,20]. Our study
also has several limitations. We did not account for the
unobserved risk in unknown HIV-exposed children, that
is, children born to HIV-positive women whose HIV infec-
tion was not diagnosed during pregnancy or breastfeed-
ing [7]. Hence our study may slightly underestimate the
risk of mother-to-child transmission in the Option B+
programme. We collected data from 21 large health
centres, district hospitals, faith-based hospitals and cen-
tral hospitals from a diverse geographical area in the
central and southern region of Malawi, but we did not
include data from the northern region, or from smaller
rural health centres. Our findings thus may not be repre-
sentative for all health facilities in Malawi.
The recent nation-wide evaluation of Malawi’s PMTCT
Programme has shown that Option B+ effectively prevents
antepartum and intrapartum transmission [14]; however,
the Option B+ policy may prevent postpartum transmission
less effectively, because many postpartum women adhere
poorly to ART, or discontinue therapy before weaning of
breastfeeding [8,9]. Two studies from Malawi have
described the risk of postpartum HIV transmission among
HIV-exposed children who were retained in care and tested
for HIV [25,26]. A cohort study from a large urban district
hospital in Malawi’s capital Lilongwe showed that 6.2% of
the enrolled children were diagnosed with HIV infection by
age 24 months. Almost half of the children were lost to
follow-up and HIV testing rates at the end of breastfeeding
were low [25]. A study from Thyolo district hospital in the
Southern region of Malawi reported that 4.1% of the HIV-
exposed children enrolled in the PMTCT programme were
diagnosed as HIV infected at 12 months of age. Two thirds
of the children were retained, but less than half of the
children were tested for HIV at 12 months [26]. Neither of
the two studies adjusted for missing data in children who
were lost to follow-up. As children at higher risk of mother-
to-child transmission are underrepresented in routine
PMTCT programmes, both studies will have underestimated
the risk of mother-to-child-transmission in the Option B+
programme [15–18]. The present analysis shows that the
degree of underestimation can be substantial. Of note, the
unweighted mother-to-child transmission rates in both stu-
dies were higher than our estimates. This may be explained
by differences in retention rates among mothers on ART at
different facilities and differences in implementation of
tracing programmes to bring children lost to follow-up
back into care [25,27].
Malawi has made huge progress in its efforts to elim-
inate HIV mother-to-child transmission. Malawi was the
first country to offer lifelong ART to all HIV-positive
pregnant and breastfeeding women under its Option B+
guidelines [13]. After Option B+ was implemented, the
ART coverage among pregnant women quickly rose: up to
80% of the HIV-positive women in Malawi received ART
during pregnancy [1]. In our study, 82% of children were
born to women who initiated ART during pregnancy,
confirming the national estimates. The high ART coverage
has led to low antepartum and intrapartum mother-to-
child transmission rates. Our study shows that the overall
transmission risk under Option B+ at the end of breast-
feeding was still low: an estimated 5.3% of the children
were infected by age 30 months. Our data suggest that
Option B+ as implemented in Malawi effectively lowers
the risk of antepartum, intrapartum and postpartum HIV
transmission.
We estimated that every second HIV-infected child
remains undiagnosed within the PMTCT programme
because retention in care is inadequate and uptake of HIV
testing is poor, especially among children born to women
who were not on ART. In line with previous studies, we
showed that children born to women who received ART are
less likely to be lost to follow-up and more likely to be
tested for HIV [15–18]. Efforts to increase retention and HIV
testing could improve the diagnosis of HIV-infected children
and their access to ART. Better retention could also
improve poor health outcomes among HIV-exposed unin-
fected children [28]. Interventions to improve retention
should address possible drivers of loss to follow-up, includ-
ing non-disclosure of HIV status, low socio-economic status
of parents, low maternal education, lack of support from
family members and partners and fear of stigma [29–31].
An integrated infant tracing programme in which commu-
nity health workers traced HIV-exposed children was highly
successful: 77% of the defaulters could be reached by
phone or home visit, and 95% of them returned to care
[32]. A similar tracing intervention at a large district hospi-
tal in Lilongwe was less successful: only half of the children
could be traced and only one-third of those who were
located could be returned to care [25]. Conditional cash
transfers or transport reimbursements are other possible
interventions to improve retention in care [33]. HIV testing
within PMTCT programmes could be improved by addres-
sing logistical challenges such as shortages of dried blood
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spot sample test kits [34]. Additionally, HIV testing could be
performed in paediatric in-patient and out-patient clinics to
ensure access to ART of HIV-positive children who dropped
out of PMTCT programmes [35].
Conclusions
Confirmed HIV mother-to-child transmission rates in Malawi’s
Option B+ programme are low, but due to poor retention,
less than half of the HIV-infected children were diagnosed.
Figure 4. Percentages of HIV-exposed children not yet enrolled, retained in care, discharged HIV-negative, lost to follow-up, initiated ART
or dead.
The coloured areas show the percentage of children in the corresponding state at the given time. Children were discharged confirmed HIV-
free if they were tested HIV-negative at least 6 weeks after cease of breastfeeding. Children were considered lost to follow-up if they had
missed a clinic appointment for more than 60 days and did not return to care thereafter.
Figure 3. Unweighted and weighed cumulative incidence of HIV infection in HIV-exposed children.
Estimates of the cumulative incidence of HIV infection among all children enrolled into care from unweighted and weighted analyses. The
weighted analyses correct for unobserved test results in children lost to follow-up or not tested Shaded areas show 95% confidence intervals.
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We recommend expansion of tracing of children lost to
follow-up and HIV testing in outpatient clinics to ensure
that all HIV-positive children have access to early ART.
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Table 2. Multivariable analysis of predictors of time to enrolment, loss to follow-up, discharged HIV-negative, ART initiation and
mortality
Enrolment Loss to follow-up Discharge HIV- ART initiation Mortality
aHR 95% CI aHR 95% CI aHR 95% CI aHR 95% CI aHR 95% CI
Gender
Male 1 1 1 1 1
Female 0.99 (0.95–1.03) 1.02 (0.96–1.08) 0.97 (0.87–1.08) 1.16 (0.88–1.53) 0.88 (0.53–1.48)
Unknown 0.98 (0.89–1.06) 1.13 (0.99–1.29) 1.12 (0.84–1.49) 0.76 (0.35–1.64) 1.37 (0.48–3.94)
Age at enrolment (months) NA 1.13 (1.12–1.14) 1.00 (0.99–1.01) 1.23 (1.18–1.29) 1.12 (1.02–1.23)
Birthweight
≥2.5 kg 1 1 1 1 1
<2.5 kg 0.96 (0.91–1.01) 0.98 (0.89–1.07) 0.88 (0.74–1.05) 1.71 (1.17–2.52) 2.72 (1.52–4.85)
Missing 0.70 (0.67–0.74) 0.95 (0.89–1.02) 0.99 (0.88–1.13) 1.14 (0.83–1.55) 0.73 (0.38–1.41)
Antepartum ARV exposure
None 1 1 1 1 1
ART <4 weeks 1.14 (1.01–1.29) 0.77 (0.65–0.91) 0.93 (0.68–1.26) 0.45 (0.22–0.94) 0.22 (0.05–1.01)
ART ≥4 weeks 1.23 (1.10–1.37) 0.62 (0.54–0.72) 1.08 (0.84–1.38) 0.25 (0.13–0.48) 0.36 (0.12–1.11)
Unknown 1.14 (0.99–1.31) 0.84 (0.69–1.02) 0.84 (0.58–1.22) 0.45 (0.18–1.14) 0.46 (0.09–2.47)
Intrapartum ARV exposure
None 1 1 1 1 1
sdNVP 1.01 (0.88–1.16) 1.11 (0.91–1.35) 0.97 (0.70–1.34) 0.57 (0.22–1.48) 1.21 (0.34–4.31)
ART 1.03 (0.92–1.14) 1.06 (0.92–1.23) 0.85 (0.68–1.07) 0.85 (0.45–1.60) 0.76 (0.24–2.39)
Unknown 1.08 (0.94–1.24) 1.20 (0.99–1.45) 1.01 (0.70–1.46) 0.33 (0.11–1.03) 0.21 (0.03–1.42)
NVP at birth
None 1 1 1 1 1
Yes 1.46 (1.33–1.59) 0.93 (0.83–1.06) 1.04 (0.85–1.28) 0.46 (0.29–0.75) 0.75 (0.30–1.88)
Unknown 1.07 (0.93–1.23) 1.02 (0.84–1.23) 1.27 (0.87–1.85) 0.95 (0.38–2.41) 1.06 (0.23–4.93)
NVP after birth
None 1 1 1 1 1
Yes 1.28 (1.20–1.36) 0.95 (0.86–1.05) 1.04 (0.88–1.23) 0.83 (0.53–1.29) 0.93 (0.41–2.08)
Unknown 1.22 (1.12–1.32) 1.24 (1.10–1.40) 0.86 (0.69–1.08) 0.82 (0.45–1.49) 2.80 (1.15–6.80)
Facility type
Faith-based Hospital 1 1 1 1 1
Health Centre 1.14 (1.05–1.24) 1.38 (1.22–1.56) 0.83 (0.56–1.23) 0.79 (0.43–1.47) 0.00 (0.00->100)
District Hospital 1.33 (1.25–1.42) 0.83 (0.75–0.92) 1.56 (1.27–1.92) 0.84 (0.54–1.30) 0.45 (0.23–0.87)
Central Hospital 1.59 (1.46–1.73) 1.22 (1.08–1.39) 2.33 (1.76–3.08) 0.77 (0.39–1.49) 0.87 (0.37–2.07)
aHR: adjusted hazards ratios; CI: confidence interval; ARV: antiretroviral drugs; ART: antiretroviral therapy; NVP: nevirapine prophylaxis.
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